• ScanSource, Inc. has already reported full-year results for the period ended June 30, 2026, with sales rising to US$3.23 billion and net income improving to US$78.87 million, alongside higher basic and diluted earnings per share from continuing operations.
• Alongside these results, ScanSource issued guidance for fiscal 2027 calling for mid‑single‑ to high‑single‑digit net sales growth, while its Board adjusted to seven members following the retirement of long‑serving director Peter C. Browning.
• We’ll examine how ScanSource’s earnings growth and 2027 sales guidance shape its investment narrative following the recent share price move.

AI is about to change healthcare. These 40 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

What Is ScanSource's Investment Narrative?

To own ScanSource, you need to be comfortable with a mid-sized distributor that is trying to pivot more of its business toward higher-margin, recurring technology and communications solutions while still operating on thin net margins. The latest full-year results and the 6% to 10% sales growth outlook for 2027 broadly support that story, and the recent share price gain suggests the market has welcomed the update rather than seeing it as a major reset of expectations. In the short term, key catalysts remain execution on the Launch Point initiatives, integration of recent acquisitions and continued share repurchases, with the new earnings guidance reinforcing, rather than redefining, those themes. The bigger risks look unchanged: low returns on equity, modest forecast growth and execution risk as leadership responsibilities shift on a slightly smaller board.

However, one governance and capital allocation issue in particular is worth a closer look for shareholders. ScanSource's shares have been on the rise but are still potentially undervalued by 15%. Find out what it's worth.

Exploring Other Perspectives

Two Simply Wall St Community fair values, from US$46.44 to US$60.50, show how differently private investors view ScanSource. When you weigh that against thin margins and low forecast returns on equity, it underlines why sentiment on the shares can shift quickly.

Explore 2 other fair value estimates on ScanSource - why the stock might be worth as much as 8% more than the current price!

Form Your Own Verdict

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your ScanSource research is our analysis highlighting 3 key rewards that could impact your investment decision.
• Our free ScanSource research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate ScanSource's overall financial health at a glance.

Ready To Venture Into Other Investment Styles?

Every day counts. These free picks are already gaining attention. See them before the crowd does:

• The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 18 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.
• Uncover the next big thing with 22 elite penny stocks that balance risk and reward.
• This technology could replace computers: discover 24 stocks that are working to make quantum computing a reality.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.